Satellos Bioscience Inc.

MSLE Healthcare Biotechnology

In the quarter to June 2026, EPS fell 42.5% and free cash flow fell 65.7%, each against the same quarter a year earlier.

6.46 0.38 −5.56%
Market cap
$145.1M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
10.70 7.77 16.48 11.22
Net Debt/EBITDA
5.80 3.62 6.96 5.08
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.30) (0.50) (0.52) (0.39)
Book value per Share
2.44 1.90 3.83 2.88
Free Cash Flow
(4.13) (7.26) (9.59) (8.03)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates